Harvard Bioscience (NASDAQ: HBIO) CFO awarded 30,000 RSUs in equity grant

Rhea-AI Filing Summary

Harvard Bioscience Chief Financial Officer Mark T. Frost reported an equity compensation grant rather than a market trade. He acquired 30,000 restricted stock units (RSUs) at no cost, which will vest in three equal installments on March 20, 2027, 2028, and 2029, subject to his award agreement. After this grant, he is shown with 47,500 common stock equivalents, including 5,000 shares purchased on March 16, 2026, 10,000 additional RSUs scheduled to vest on May 12, 2026, and 2,500 shares of common stock beneficially owned. The filing also notes that these RSU and share counts were adjusted to reflect a 10-for-1 reverse stock split that took effect on March 13, 2026.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Frost Mark T

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	30,000	$0.00	--

Holdings After Transaction: Common Stock — 47,500 shares (Direct)

Footnotes (1)

1. Includes (a) an award granting 30,000 restricted stock units (RSUs) that will vest in three equal installments on March 20, 2027, 2028, and 2029, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person, (b) 5,000 shares of common stock purchased on March 16, 2026, (c) 10,000 RSUs that will vest on May 12, 2026, and (d) 2,500 shares of common stock beneficially owned by the Reporting Person. On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 10,000 RSUs referenced in Footnote 1(c) were previously reported as covering 100,000 RSUs and the 2,500 shares of common stock referenced in Footnote 1(d) were previously reported as covering 25,000 shares of common stock. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

Key Figures

RSU grant: 30,000 RSUs Holdings after transaction: 47,500 common stock equivalents Additional RSUs: 10,000 RSUs +3 more

6 metrics

RSU grant 30,000 RSUs Award to CFO Mark T. Frost on March 20, 2026

Holdings after transaction 47,500 common stock equivalents Total reported position following RSU grant

Additional RSUs 10,000 RSUs Scheduled to vest on May 12, 2026

Previously purchased shares 5,000 shares Common stock purchased on March 16, 2026

Beneficially owned shares 2,500 shares Common stock beneficially owned by the CFO

Reverse stock split ratio 10-for-1 Reverse split effective March 13, 2026

Key Terms

restricted stock units (RSUs), reverse stock split, beneficially owned

3 terms

restricted stock units (RSUs) financial

"Includes (a) an award granting 30,000 restricted stock units (RSUs) that will vest"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

reverse stock split financial

"the common stock of Harvard Bioscience, Inc. underwent a reverse stock split"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

beneficially owned financial

"2,500 shares of common stock beneficially owned by the Reporting Person"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Frost Mark T

(Last) (First) (Middle)

C/O HARVARD BIOSCIENCE, INC.

84 OCTOBER HILL ROAD

(Street)

HOLLISTON MASSACHUSETTS 01746

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HARVARD BIOSCIENCE INC [ HBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/20/2026		A		30,000	A	$0.00	47,500(1)(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes (a) an award granting 30,000 restricted stock units (RSUs) that will vest in three equal installments on March 20, 2027, 2028, and 2029, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person, (b) 5,000 shares of common stock purchased on March 16, 2026, (c) 10,000 RSUs that will vest on May 12, 2026, and (d) 2,500 shares of common stock beneficially owned by the Reporting Person.

2. On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 10,000 RSUs referenced in Footnote 1(c) were previously reported as covering 100,000 RSUs and the 2,500 shares of common stock referenced in Footnote 1(d) were previously reported as covering 25,000 shares of common stock. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

	/s/ Mark Frost	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Harvard Bioscience (HBIO) disclose about CFO Mark Frost in this Form 4?

Harvard Bioscience reported that CFO Mark T. Frost received a grant of 30,000 restricted stock units at no cost. These equity awards are compensation, not open-market purchases or sales, and increase his reported holdings to 47,500 common stock equivalents.

How many RSUs did Harvard Bioscience (HBIO) grant to its CFO and when do they vest?

The CFO received 30,000 restricted stock units from Harvard Bioscience. These RSUs vest in three equal installments on March 20, 2027, 2028, and 2029, subject to the terms of his award agreement with the company.

What is CFO Mark Frost’s total reported stake in Harvard Bioscience (HBIO) after this transaction?

After the grant, Mark Frost is reported with 47,500 common stock equivalents. This includes 30,000 new RSUs, 10,000 RSUs vesting May 12, 2026, 5,000 shares bought March 16, 2026, and 2,500 shares of common stock beneficially owned.

Did Harvard Bioscience (HBIO) complete a reverse stock split affecting the CFO’s holdings?

Yes. On March 13, 2026, Harvard Bioscience completed a 10-for-1 reverse stock split. Previously reported 100,000 RSUs and 25,000 shares held by the CFO were adjusted to 10,000 RSUs and 2,500 shares to reflect this split.

Were CFO Mark Frost’s recent Harvard Bioscience (HBIO) equity changes open-market trades?

The Form 4 shows a compensation-related award of 30,000 RSUs, not an open-market trade. It also notes previously purchased 5,000 shares on March 16, 2026, but the featured transaction itself is a grant or award acquisition.